| Literature DB >> 32206501 |
Jianhong An1,2,3,4, Wenli Zhang1,2, Xiaoran Jing1,2, Yao Nie1,2, Yan Xu1,5,2.
Abstract
l-isoleucine dioxygenase (IDO) is an Fe (II)/α-ketoglutarate (α-KG)-dependent dioxygenase that specifically converts l-isoleucine (l-Ile) to (2S, 3R, 4S)-4-hydroxyisoleucine (4-HIL). 4-HIL is an important drug for the treatment and prevention of type 1 and type 2 diabetes but the yields using current methods are low. In this study, the CRISPR-Cas9 gene editing system was used to knockout sucAB and aceAK gene in the TCA cycle pathway of Escherichia coli (E. coli). For single-gene knockout, the whole process took approximately 7 days. However, the manipulation time was reduced by 2 days for each round of gene modification for multigene editing. Using the genome-edited recombinant strain E. coli BL21(DE3) ΔsucABΔaceAK/pET-28a(+)-ido (2Δ-ido), the bioconversion ratio of L-Ile to 4-HIL was enhanced by about 15% compared to E. coli BL21(DE3)/pET-28a(+)-ido [BL21(DE3)-ido] strain. The CRISPR-Cas9 editing strategy has the potential in modifying multiple genes more rapidly and in optimizing strains for industrial production. © King Abdulaziz City for Science and Technology 2020.Entities:
Keywords: 4-Hydroxyisoleucine; CRISPR-Cas9; Genome editing; TCA cycle; l-Isoleucine dioxygenase
Year: 2020 PMID: 32206501 PMCID: PMC7070131 DOI: 10.1007/s13205-020-2160-3
Source DB: PubMed Journal: 3 Biotech ISSN: 2190-5738 Impact factor: 2.406